Systematic evaluation of "compliance" to prescribed treatment medications and "abstinence" from psychoactive drug abuse in chemical dependence programs: Data from the Comprehensive Analysis of Reported Drugs

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Blum, Kenneth ^a,b,f,g   Han, David ^c   Femino, John ^d   Smith, David E ^e   Saunders, Scott ^f   Simpatico, Thomas ^g   Schoenthaler, Stephen J ^h   Oscar Berman, Marlene ⁱ   Gold, Mark S ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Path Foundation NY   (United States)

^c UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^d Meadows Edge Recovery Center   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Dominion Diagnostics   (United States)

^g UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^h CALIFORNIA STATE UNIVERSITY   (United States)

ⁱ BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMPHETAMINE DERIVATIVE; ANALGESIC AGENT; ANTITUSSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CANNABINOID; COCAINE; OPIATE; OPIATE ANTAGONIST; PSYCHEDELIC AGENT; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT;

ARTICLE; DRUG ABUSE; DRUG WITHDRAWAL; HUMAN; MONITORING; OBSERVATIONAL STUDY; PATIENT CARE; PATIENT COMPLIANCE; PRESCRIPTION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; UNITED STATES; LONGITUDINAL STUDY; PROCEDURES; SUBSTANCE ABUSE; SUBSTANCE-RELATED DISORDERS; URINE;

HUMANS; LONGITUDINAL STUDIES; PATIENT COMPLIANCE; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 84907584853     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104275     Document Type: Article

References (45)

1. Gilbert JW, Wheeler GR, Mick GE, Storey BB, Herder SL, et al. (2010) Importance of urine drug testing in the treatment of chronic noncancer pain: implications of recent medicare policy changes in Kentucky. Pain Physician 13:167-186.
2. Jacobs W, DuPont R, Gold MS (2000) Drug testing and the DSM V. Psychiat Ann 30: 583-588.
3. Goldberger BA, Frost-Pineda K, Gold MS (2003) Methodone related deaths exceed heroin in the state of Florida. J Addict Dis 22:139.
4. Jacobs WS, Repetto M, Vinson S, Pomm R, Gold MS (2004) Random urine testing as an intervention for drug addiction. Psychiatr Ann 34: 781-785.
5. McCusker RR, Fuehrlein B, Goldberger BA, Gold MS, Cone EJ (2006) Technical brief: caffeine content of decaffeinated coffee. J Anal Toxicol 30: 611-613.
6. Gold MS, Frost-Pineda K (2006) Problem doctors: Is there a system-level solution? Letter to the Editor. Ann Intern Med 144: 861-862.
7. Gold MS, Frost-Pineda K, Goldberger BA, DuPont RL (2006) Physicians and Drug Screening. Letter to the Editor. J Adolesc Health 39: 154-155.
8. Merlo LJ, Gold MS (2008) Increased assessment and monitoring needed for methadone patients. Author reply. Am J Med 121: e25.
9. Merlo L, Gold M (2008) Prescription Opioid Abuse and Dependence Among Physicians: Hypotheses and Treatment. Harv Rev Psychiatry 16: 181-194.
10. Graham NA, Merlo LJ, Goldberger BA, Gold MS (2008) Methadone and heroin-related deaths in Florida. Am J Drug Alcohol Abuse 24: 347-353.
11. DuPont RL, McLellan AT, White WL, Merlo LJ, Gold MS (2009) Setting the standard for recovery: Physicians' Health Programs J Subst Abuse Treat 36: 159-171.
12. Bailey JA, Hurley RW, Gold MS (2010) Crossroads of Pain and Addiction. Pain Med 11: 1803-1818.
13. Reisfield GM, Graham NA, Gold MS (2011) RE: "Estimates of nondisclosure of cigarette smoking among pregnant and nonpregnant women of reproductive age in the United States". Letter to the Editor. Am J Epidemiol 173: 1095-1096.
14. DuPont RL, Goldberger BA, Gold MS (2011) Clinical and legal considerations in drug testing. In: Chris Cavacuiti editor. Principals of Addiction Medicine-The Essentials. Baltimore, MD: Lippincott Williams & Wilkins.
15. Reisfield GM, Goldberger, Gold MS, DuPont RL (2012) The Mirage of Impairing Drug Concentration Thresholds: A Rationale for Zero Tolerance Per Se Driving under the Influence of Drugs Laws. J Anal Toxicol 36: 353-356.
16. Goldberger BA, Martin DM, Gold MS (2013) Afghanistan Treatment Center Study: Children's Hair, Oral Fluid, and Urine Random Drug Testing. In: Afghanistan National Urban Drug Use Survey, 2012. Washington, DC: U. S. Department of State, Bureau of International Narcotics and Law Enforcement Affairs. pp. A104-A126.
17. Fuehrlein BS, Gold MS (2013) Medication Assisted Recovery in Alcohol and Opioid Dependence. Dir Psychiatry 33: 15-27.
18. Greene W, Gold MS (2015) Section 16: Drug Abuse. In: Bope ET, Kellerman RD, (Eds.) Conn's Current Therapy 2015. Philadelphia: Saunders, Inc. pp. 946-951.
19. Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, et al. (2004) Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 75: 37-45.
20. Campbell J, Nickel EJ, Penick EC, Wallace D, Gabrielli WF, et al. (2003) Comparison of desipramine or carbamazepine to placebo for crack cocainedependent patients. Am J Addict 12: 122-136.
21. Shaner A, Roberts LJ, Eckman TA, Tucker DE, Tsuang JW, et al. (1997) Monetary reinforcement of abstinence from cocaine among mentally ill patients with cocaine dependence. Psychiatr Serv 48: 807-810.
22. Starrels JL, Becker WC, Alford DP, Kapoor A, Williams AR, et al. (2010) Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med 152: 712-720.
23. Longshore D, Annon J, Anglin MD, Rawson RA (2005) Levo-alphaacetylmethadol (LAAM) versus methadone: treatment retention and opiate use. Addiction 100: 1131-1139.
24. Simpson DD, Joe GW, Fletcher BW, Hubbard RL, Anglin MD (1999) A national evaluation of treatment outcomes for cocaine dependence. Arch Gen Psychiatry 56:507-514.
25. DuPont RL, Gold MS (1995) Withdrawal and reward: Implications for detoxification and relapse prevention. Psychiatr Ann 25: 663-668.
26. DuPont RL, Skipper GE (2012) Six lessons from state physician health programs to promote long-term recovery. J Psychoactive Drugs 44: 72-78.
27. DuPont RL, McLellan AT, Carr G, Gendel M, Skipper GE (2009) How are addicted physicians treated? A national survey of Physician Health Programs. J Subst Abuse Treat 37: 1-7.
28. Standridge JB, Adams SM, Zotos AP (2010) Urine drug screening: a valuable office procedure. Am Fam Physician 81: 635-640.
29. Tenore PL (2010) Advanced urine toxicology testing. J Addict Dis 29: 436-448.
30. McCarberg BH (2011) A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management. Postgrad Med 123: 124-31. doi: 10.3810/pgm.2011.11.2502.
31. Bruer JT (1982) Methodological rigor and citation frequency in patient compliance literature. Am J Public Health 72: 1119-1123.
32. Chong WW, Aslani P, Chen TF (2011) Effectiveness of interventions to improve antidepressant medication adherence: a systematic review. Int J Clin Pract 65:954-975.
33. Anderson IM, Tomenson BM (1995) Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a metaanalysis. BMJ 310: 1433-1438.
34. Steffens DC, Krishnan KR, Helms MJ (1997) Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 6: 10-18.
35. Montgomery SA, Kasper S (1995) Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol 9: 33-40.
36. Anderson IM (1998) SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7: 11-17.
37. Dahlgren A, Wargelius HL, Berglund KJ, Fahlke C, Blennow K, et al. (2011) Do alcohol-dependent individuals with DRD2 A1 allele have an increased risk of relapse? A pilot study. Alcohol Alcohol 46: 509-513.
38. Comings DE, MacMurray J, Johnson P, Dietz G, Muhleman D (1995) Dopamine D2 receptor gene (DRD2) haplotypes and the defense style questionnaire in substance abuse, Tourette syndrome, and controls. Biol Psychiatry 37: 798-805.
39. Katz N, Fanciullo GJ (2002) Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain 18: 76-82.
40. McLellan AT, Lewis DC, O'Brien CP, Kleber HD (2000) Drug dependence, a chronic medical illness: implications for treatment, insurance and outcomes evaluation. JAMA 284: 1689-1695.
41. Volkow ND, Tomasi D, Wang GJ, Telang F, Fowler JS, et al. (2013) Predominance of D2 Receptors in Mediating Dopamine's Effects in Brain Metabolism: Effects of Alcoholism. J Neurosci. 2013: 33: 4527-35.
42. Archer T, Oscar-Berman M, Blum K, Gold M (2013) Epigenetic Modulation of Mood Disorders. J Genet Syndr Gene Ther 4(120): pii: 1000120.
43. Zhang H (2013) Profiling epigenomic and trasciptomic alteration in postmortem prefrontal cortex of human alcoholcs. J Addic. Res. and Therp. 4: 57 (abstract)
44. 2013. Proceedings of 2nd International conference on Addiction Research & Therapy, Las Vegas, NV 22-24, USA.
45. Reisfield GM, Graham NA, Gold MS (2010) Urine drug testing is still an invaluable resource for primary care. Ann Intern Med 153:420; author reply 420-421.